CRLs are not always the end of the world. They can highlight any deficiency in an application and could be a minor issue. There is a process to address CRLs and they do not always end in a withdraw of the application.
The FDA would not have been sitting on the backside for 30 days. I would figure that MSB has significant diaglog during the application. This would also include inspection of the manufacturing facilities at Lonza.
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=314.110
Ann: Trading Halt, page-410
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.056B | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2110 | 96.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 88.0¢ | 12493 | 4 |
View Market Depth
| Last trade - 09.57am 10/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |
Day chart unavailable